11. DEVELOPMENT OF NOVEL PRECLINICAL MODELS OF SECONDARY RESISTANCE TO THE PI3KΔ INHIBITOR IDELALISIB IN SPLENIC MARGINAL ZONE LYMPHOMA (SMZL). (June 2017) Authors: Arribas, A.J.; Gaudio, E.; Rinaldi, A.; Cascione, L.; Tarantelli, C.; Kwee, I.; Stathis, A.; Zucca, E.; Rossi, D.; Bertoni, F. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 254 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
12. EG‐011 IS A NOVEL SMALL MOLECULE WITH IN VITRO AND IN VIVO ANTI‐TUMOR ACTIVITY AGAINST LYMPHOMA. (12th June 2019) Authors: Gaudio, E.; Spriano, F.; Tarantelli, C.; Guala, M.; Riveiro, E.; Golino, G.; Lupia, A.; Costa, G.; Rocca, R.; Cascione, L.; Jenni, S.; Tsai, Y.; Bornhauser, B.; Alcaro, S.; Paduano, F.; Trapasso, F.; Zucca, E.; Stathis, A.; Pazzi, N.; Cavalli, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 513 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
13. Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy. (June 2017) Authors: Bruscaggin, A.; Spina, V.; Di Trani, M.; Martini, M.; Locatelli, S.; Cupelli, E.; Forestieri, G.; Condoluci, A.; Cuccaro, A.; Moccia, A.; Stathis, A.; Manzoni, M.; Deambrogi, C.; Diop, F.; Stüssi, G.; Cavalli, F.; Bertoni, F.; Zucca, E.; Larocca, L.M.; Gaidano, G. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
14. Improving responses to dual PI3K/BCL2 inhibition in lymphomas: results of a pharmacological screen with over 1, 400 compounds. (October 2022) Authors: Arribas, A.; Chiappa, M.; Napoli, S.; Cannas, E.; Cascione, L.; Spriano, F.; Tarantelli, C.; Rossi, D.; Zucca, E.; Alimonti, A.; Stathis, A.; Damia, G.; Broggini, M.; Bertoni, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
15. INTEGRATION BETWEEN METABOLIC TUMOUR VOLUME AND METABOLIC HETEROGENEITY PREDICTS OUTCOME OF DLBCL LYMPHOMA PATIENTS IN THE SAKK 38/07 STUDY COHORT. (12th June 2019) Authors: Ceriani, L.; Pirosa, M.; Stathis, A.; Gritti, G.; Ruberto, T.; Bruno, A.; Moccia, A.; Rambaldi, A.; Ferrari, S.; Giovannella, L.; Hayoz, S.; Mazzucchelli, L.; Dirnhofer, S.; Mamot, C.; Zucca, E. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 77 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
16. MECHANISMS OF SECONDARY RESISTANCE TO IDELALISIB IN MARGINAL ZONE LYMPHOMA. (12th June 2019) Authors: Arribas, A.; Napoli, S.; Gaudio, E.; Cascione, L.; Di Veroli, A.; Tarantelli, C.; Spriano, F.; Zucchetto, A.; Rossi, F.; Rinaldi, A.; Stathis, A.; Stussi, G.; Gattei, V.; Cruciani, G.; Zucca, E.; Rossi, D.; Bertoni, F. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 319 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
17. Non-ATP competitive inhibition of PI3Kδ with IOA-244 shows anti-lymphoma activity. (October 2022) Authors: Tarantelli, C.; Spriano, F.; Cascione, L.; Civanelli, E.; Cannas, E.; Mensah, A.A.; Arribas, A.J.; Rinaldi, A.; Stathis, A.; Di Conza, G.; Niewola-Staszkowska, K.; Lahn, M.; Bertoni, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S80 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
18. P1114: ZANDELISIB ON INTERMITTENT DOSING AS A SINGLE AGENT OR IN COMBINATION WITH RITUXIMAB OR ZANUBRUTINIB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): RESULTS FROM A MULTI-ARM PHASE 1B STUDY. (23rd June 2022) Authors: Soumerai, J. D.; Jagadeesh, D.; Salman, H.; Samaniego, F.; Patel, K.; Stathis, A.; Reddy, N.; Kenkre, V. P.; Asch, A.; Diefenbach, C.; Lossos, I. S.; Persky, D.; Awan, F.; Huang, W.; Vandever, K.; Zelenetz, A. D. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1004 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
19. Pharmacological screening identified promising combination partners in marginal zone lymphoma models with secondary resistance to BTK and PI3K inhibitors. (October 2022) Authors: Arribas, A.; Vultaggio, S.; Andronache, A.; Robusto, M.; Fancelli, D.; Cannas, E.; Spriano, F.; Tarantelli, C.; Rossi, D.; Zucca, E.; Stathis, A.; Varasi, M.; Mercurio, C.; Bertoni, F. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S108 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
20. Phase 1 study of first-in-class dUTPase inhibitor, TAS-114 in combination with S-1 in patients with advanced solid tumors. (December 2016) Authors: Aoyama, T.; Fasolo, A.; Stathis, A.; Sessa, C.; Hollebecque, A.; Soria, J.C.; Pastorino, A.; Alberto Sobrero, A.S.; Van Laethem, J.L.; Saito, K.; Yoshida, K.; Winkler, R.; Benedetti, F.; Gianni, L. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗